Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

BACKGROUND: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.

Bibliographic Details
Main Authors: Chae, Young Kwang, Brown, Erika N., Lei, Xiudong, Melhem-Bertrandt, Amal, Giordano, Sharon H., Litton, Jennifer K., Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana M., Chavez-MacGregor, Mariana
Format: Online
Language:English
Published: Ivyspring International Publisher 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753529/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753529/

Similar Items